• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在大流行期间启动的 2019 年冠状病毒病随机临床试验的多发性特征。

Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.

机构信息

The University of Texas MD Anderson Cancer Center, Houston.

出版信息

JAMA Netw Open. 2020 Jul 1;3(7):e2015100. doi: 10.1001/jamanetworkopen.2020.15100.

DOI:10.1001/jamanetworkopen.2020.15100
PMID:32658285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7358910/
Abstract

This systematic review examines current randomized clinical trials of therapeutic agents to treat coronavirus disease 2019 (COVID-19).

摘要

这篇系统综述考察了目前治疗 2019 年冠状病毒病（COVID-19）的治疗药物的随机临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c999/7358910/fabf256f91a1/jamanetwopen-3-e2015100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c999/7358910/fabf256f91a1/jamanetwopen-3-e2015100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c999/7358910/fabf256f91a1/jamanetwopen-3-e2015100-g001.jpg

相似文献

1
Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.在大流行期间启动的 2019 年冠状病毒病随机临床试验的多发性特征。
JAMA Netw Open. 2020 Jul 1;3(7):e2015100. doi: 10.1001/jamanetworkopen.2020.15100.
2
Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.治疗新型冠状病毒肺炎的研究性疗法：正在进行的临床试验的最新情况
Eur Urol Focus. 2020 Sep 15;6(5):1028-1031. doi: 10.1016/j.euf.2020.05.019. Epub 2020 Jun 5.
3
Treatment of SARS-CoV-2: How far have we reached?新型冠状病毒肺炎的治疗：我们已经取得了多大进展？
Drug Discov Ther. 2020 May 6;14(2):67-72. doi: 10.5582/ddt.2020.03008. Epub 2020 Apr 25.
4
Audio Interview: New Data on Remdesivir in Covid-19.音频访谈：瑞德西韦治疗新冠病毒病的新数据
N Engl J Med. 2020 May 28;382(22):e94. doi: 10.1056/NEJMe2019975.
5
Race to find COVID-19 treatments accelerates.寻找新冠病毒治疗方法的竞赛加速。
Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.
6
Some drugs for COVID-19.一些用于治疗新冠肺炎的药物。
Med Lett Drugs Ther. 2020 Apr 6;62(1595):49-50.
7
Why do COVID death rates seem to be falling?为什么新冠死亡率似乎在下降？
Nature. 2020 Nov;587(7833):190-192. doi: 10.1038/d41586-020-03132-4.
8
Clinical management of COVID-19.《COVID-19 的临床管理》
Indian J Med Res. 2020 May;151(5):401-410. doi: 10.4103/ijmr.IJMR_957_20.
9
Treatment options for COVID-19: The reality and challenges.治疗 COVID-19 的选择：现实与挑战。
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4.
10
Psychopharmacology of COVID-19.新型冠状病毒肺炎的精神药理学。
Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18.

引用本文的文献

1
Completion and reporting of COVID-19 clinical trials registered on ClinicalTrials.gov during the first 6 months of the pandemic: cohort study.大流行期间 ClinicalTrials.gov 上注册的 COVID-19 临床试验的完成和报告：队列研究。
BMJ Open. 2024 Nov 14;14(11):e085906. doi: 10.1136/bmjopen-2024-085906.
2
External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations.外部对照臂：新冠疫情揭示了在临床和公共卫生调查中实时使用真实世界证据的优点。
Front Med (Lausanne). 2023 Jul 6;10:1198088. doi: 10.3389/fmed.2023.1198088. eCollection 2023.
3

本文引用的文献

1
Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis.寻找新冠病毒病的有效治疗方法：危机时刻的科学诚信与公众信心
JAMA. 2020 May 19;323(19):1899-1900. doi: 10.1001/jama.2020.6434.
2
Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.在大流行期间治疗新冠病毒病——超说明书用药、同情用药及随机临床试验
JAMA. 2020 May 19;323(19):1897-1898. doi: 10.1001/jama.2020.4742.
3
Multiplicity in oncology randomised controlled trials: a threat to medical evidence?
Disparities in COVID-19 clinical studies from high-income and low-and middle-income countries.
高收入和中低收入国家 COVID-19 临床研究中的差异。
Int J Infect Dis. 2023 Jul;132:9-16. doi: 10.1016/j.ijid.2023.04.393. Epub 2023 Apr 15.
4
Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience.瑞德西韦对COVID-19住院患者鼻咽拭子标本中SARS-CoV-2 RNA病毒载量动力学的影响：一项真实病例经验
Microorganisms. 2023 Jan 25;11(2):312. doi: 10.3390/microorganisms11020312.
5
Competition for recruitment in SARS-CoV-2 Trials in the United States: a longitudinal cohort analysis.美国 SARS-CoV-2 临床试验中的招募竞争：一项纵向队列分析。
BMC Res Notes. 2022 Dec 12;15(1):368. doi: 10.1186/s13104-022-06263-1.
6
[Challenges of Investigator-initiated Clinical Trials to Support 
the New Drug Development].[研究者发起的支持新药研发的临床试验面临的挑战]
Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):511-516. doi: 10.3779/j.issn.1009-3419.2022.102.31.
7
How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov.早期 SARS-CoV-2 治疗和预防试验有多大信息量？对 ClinicalTrials.gov 上注册的试验进行的纵向队列分析。
PLoS One. 2022 Jan 21;17(1):e0262114. doi: 10.1371/journal.pone.0262114. eCollection 2022.
8
Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.托珠单抗治疗与 COVID-19 患者临床结局的相关性：系统评价和荟萃分析。
Aging (Albany NY). 2022 Jan 17;14(2):557-571. doi: 10.18632/aging.203834.
9
Reliability of Trial Information Across Registries for Trials With Multiple Registrations: A Systematic Review.多注册试验的注册库间试验信息的可靠性：系统评价。
JAMA Netw Open. 2021 Nov 1;4(11):e2128898. doi: 10.1001/jamanetworkopen.2021.28898.
10
Collaborative Platform Trials to Fight COVID-19: Methodological and Regulatory Considerations for a Better Societal Outcome.合作平台试验抗击 COVID-19：为实现更好的社会效益的方法学和监管考虑。
Clin Pharmacol Ther. 2021 Aug;110(2):311-320. doi: 10.1002/cpt.2183. Epub 2021 Mar 16.
肿瘤学随机对照试验中的多样性：对医学证据的一种威胁？
Lancet Oncol. 2019 Dec;20(12):1638-1640. doi: 10.1016/S1470-2045(19)30744-2.
4
Ethics of randomized trials in a public health emergency.突发公共卫生事件中随机试验的伦理问题
PLoS Negl Trop Dis. 2018 May 17;12(5):e0006313. doi: 10.1371/journal.pntd.0006313. eCollection 2018 May.
5
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.系统评价与Meta分析的首选报告项目：PRISMA声明。
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64. doi: 10.7326/0003-4819-151-4-200908180-00135. Epub 2009 Jul 20.